These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 21923231)

  • 1. Acute effects of interleukin-6 infusion on apo-B-containing lipoprotein subclasses in humans.
    Bagdade J; Pedersen BK; Schwenke D; Saremi A; Alaupovic P
    Scand J Clin Lab Invest; 2011 Oct; 71(6):449-55. PubMed ID: 21923231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CETP-mediated cholesteryl ester enrichment of apoB subclasses in type 1 diabetes.
    Bagdade JD; Knight-Gibson C; Simpson N; Gerkin R; Alaupovic P; Reardon C
    Eur J Clin Invest; 2012 Jul; 42(7):709-16. PubMed ID: 22288873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein-B subclasses as acceptors of cholesteryl esters transferred by CETP.
    Lee DM; Alaupovic P; Knight-Gibson C; Bagdade JD
    Eur J Clin Invest; 2008 Oct; 38(10):734-42. PubMed ID: 18761668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde.
    Luc G; Fievet C; Arveiler D; Evans AE; Bard JM; Cambien F; Fruchart JC; Ducimetiere P
    J Lipid Res; 1996 Mar; 37(3):508-17. PubMed ID: 8728314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency.
    Alaupovic P; Attman PO; Knight-Gibson C; Mulec H; Weiss L; Samuelsson O
    Kidney Int; 2006 May; 69(10):1865-71. PubMed ID: 16572113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of remnant accumulation markers on plasma concentrations of two lipoprotein(a) subspecies (containing or free of apoE).
    Bach-Ngohou K; Giraud F; Krempf M; Bard JM
    Metabolism; 2001 Mar; 50(3):277-82. PubMed ID: 11230778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein-defined lipoprotein abnormalities in rheumatoid arthritis patients and their potential impact on cardiovascular disease.
    Knowlton N; Wages JA; Centola MB; Alaupovic P
    Scand J Rheumatol; 2012 May; 41(3):165-9. PubMed ID: 22401593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LpA-II:B:C:D:E: a new immunochemically-defined acute phase lipoprotein in humans.
    Bagdade JD; Jilma B; Hudgins LC; Alaupovic P; McCurdy CE
    Lipids Health Dis; 2018 May; 17(1):127. PubMed ID: 29807532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoproteins E and C-III in apo B- and non-apo B-containing lipoproteins in middle-aged women from the Stanislas cohort: effect of oral contraceptive use and common apolipoprotein E polymorphism.
    Starck M; Schiele F; Herbeth B; Vincent-Viry M; Beaud B; Siest G; Visvikis S
    Atherosclerosis; 2001 Apr; 155(2):509-16. PubMed ID: 11254923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of lipids, lipoproteins, and apolipoproteins in Menkes' disease.
    Blackett PR; Lee DM; Donaldson DL; Fesmire JD; Chan WY; Holcombe JH; Rennert OM
    Pediatr Res; 1984 Sep; 18(9):864-70. PubMed ID: 6483510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.
    Dinkel RE; Barrett PH; Demant T; Parhofer KG
    Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid and apolipoproteins (ApoAI, ApoB, Apo CIII, ApoE) disturbance in hemodialysis (HD) and renal transplant (Tx) patients.
    Janicki K; Solski J; Janicka L; Kimak E; Bednarek-Skublewska A; Stettner S; Molas G
    Ann Univ Mariae Curie Sklodowska Med; 2004; 59(1):459-66. PubMed ID: 16146031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E.
    Clavey V; Lestavel-Delattre S; Copin C; Bard JM; Fruchart JC
    Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):963-71. PubMed ID: 7600129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
    Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of Apo B48, and relative Apo CII deficiency and Apo CIII enrichment in uremic very-low density lipoproteins.
    Atger V; Beyne P; Frommherz K; Roullet JB; Drüeke T
    Ann Biol Clin (Paris); 1989; 47(8):497-501. PubMed ID: 2690681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E.
    Chivot L; Mainard F; Bigot E; Bard JM; Auget JL; Madec Y; Fruchart JC
    Atherosclerosis; 1990 Jun; 82(3):205-11. PubMed ID: 2375786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological properties of apoB-containing lipoprotein particles in human atherosclerotic arteries.
    Tailleux A; Torpier G; Caron B; Fruchart JC; Fievet C
    J Lipid Res; 1993 May; 34(5):719-28. PubMed ID: 7685370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of immunochemically defined apoB-containing lipoprotein subclasses in T1D.
    Bagdade J; Knight-Gibson C; Quiroga C; Jacobson M; Lee D
    Diabetes Res Clin Pract; 2009 Sep; 85(3):265-71. PubMed ID: 19619912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentrations of apoprotein CII, CIII, and E in total serum and in the apoprotein B-containing lipoproteins, determined by a new enzyme-linked immunosorbent assay.
    Alsayed N; Rebourcet R; Chapman J
    Clin Chem; 1990 Dec; 36(12):2047-52. PubMed ID: 2253344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.